Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S326000, C546S186000, C546S207000
Reexamination Certificate
active
07915293
ABSTRACT:
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides for pharmaceutical compositions comprising the compounds described in the invention for the treatment of conditions that require inhibition of ubiquitin ligases. Furthermore, the invention provides for methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound according to the invention.
REFERENCES:
patent: WO 98/05315 (1998-02-01), None
patent: WO 98/45259 (1998-10-01), None
patent: WO 2004005278 (2004-11-01), None
Hcaplus 111:146282.
Hcaplus 111:146282, “Inhibition of carbonic anhyrase by substituted benzensulfonamides. A reinvestigation by QSAR and molecular graphics analysis”, Carotti et. al., 1989.
Hcaplus 1931:16457, “Diphenyl ether series. II. Preparation and structure of some sulfonic acids and related derivatives”, 1931, Suter, C. M.
Theodora W. Greene, Protective Groups in Organic Synthesis, Third Edition, Pharmacia and Upjohn Company, John Wiley & Sons, Inc., p. 503.
Hcaplus 1981:417990 abstract, “(Phenthio)phenylamine derivatives as potential antiinflammatory compounds”, Marcincal-Lefebvre et. al., 1981.
Patani et. al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev. 1996, 96, pp. 3147-3176.
Hcaplus 1980:180816 abstract, “Diphenyl ethers and their use for treating liver infections in mammals”, 1979, Gorvin et. al.
Hcaplus Abstract 2004:41460, “Preparation of bisarylsulfonamide compounds and their use in cancer therapy”, 2004, Wang et. al.
Hcaplus 1960:28422, “Studies on aromatic fluorine compounds. IV. Synthesis of fluorine-containing toluenes and their derivatives”, Fukui et. al., 1958.
Hcaplus 2000:553560, “Preparation of substituted N-heterocyclyl benzamides and analogs as G-protein coupled heptahelical receptor binding compounds”, Shiosaki et. al., 2000.
Badawi, A., et al., “Uracil, 2,4-Dichlorophenol and Diphenylether Derivatives with Antimicrobial Activity,”Pharmazie, vol. 38 (1983)pp. 838-841.
Chau, Nguyen, et al. “Synthesis of Aromatic Polysulfonamide Esters,”Journal of Polymer Science, vol. 18 (1980) pp. 3499-3503.
Mastrukova, T.A., et al., “The Application of the Hammett Equation to the Theory of Tautomeric Equilibrium II”Tetrahedron, vol. 19 (1963) pp. 357-372.
Perola, Emanuele, et al., “Successful Virtual Screening of a Chemical Database for Farnesyltransferase Inhibitor Leads,”J. Med. Chem., vol. 43 (2000) pp. 401-408.
Tamura, Yoshinori, et al., “Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2):N-Sulfonylamino Acid Derivatives,”J. Med. Chem., vol. 41 (1998) pp. 640-649.
STN International queries, pp. 1-141.
Issakani Sarkiz D.
Look Gary Charles
Ramesh Usha V.
Singh Rajinder
McDonnell Boehnen & Hulbert & Berghoff LLP
Rahmani Niloofar
Rigel Pharmaceuticals Inc.
Seaman D. Margaret
Young Travis
LandOfFree
Ubiquitin ligase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ubiquitin ligase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ubiquitin ligase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2656248